Terms: = Skin cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
25 results:
1. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
2. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract] [Full Text] [Related]
3. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
[TBL] [Abstract] [Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S; Perrone F; Miceli R; Ascierto PA; Locati LD; Bergamini C; Granata R; Alfieri S; Resteghini C; Galbiati D; Busico A; Paielli N; Patuzzo R; Maurichi A; Gallino G; Ruggeri R; Mariani L; Palla M; Licitra L; Bossi P
Eur J Cancer; 2018 Jul; 97():7-15. PubMed ID: 29734047
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
[TBL] [Abstract] [Full Text] [Related]
7. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.
Veija T; Koljonen V; Bohling T; Kero M; Knuutila S; Sarhadi VK
BMC Cancer; 2017 Mar; 17(1):236. PubMed ID: 28359267
[TBL] [Abstract] [Full Text] [Related]
8. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.
Miller MA; Oudin MJ; Sullivan RJ; Wang SJ; Meyer AS; Im H; Frederick DT; Tadros J; Griffith LG; Lee H; Weissleder R; Flaherty KT; Gertler FB; Lauffenburger DA
Cancer Discov; 2016 Apr; 6(4):382-99. PubMed ID: 26984351
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Al-Rohil RN; Tarasen AJ; Carlson JA; Wang K; Johnson A; Yelensky R; Lipson D; Elvin JA; Vergilio JA; Ali SM; Suh J; Miller VA; Stephens PJ; Ganesan P; Janku F; Karp DD; Subbiah V; Mihm MC; Ross JS
Cancer; 2016 Jan; 122(2):249-57. PubMed ID: 26479420
[TBL] [Abstract] [Full Text] [Related]
10. The genetic basis of new treatment modalities in melanoma.
Kunz M
Curr Drug Targets; 2015; 16(3):233-48. PubMed ID: 25654738
[TBL] [Abstract] [Full Text] [Related]
11. Dermatological toxicity associated with targeted therapies in cancer: optimal management.
Peuvrel L; Dréno B
Am J Clin Dermatol; 2014 Oct; 15(5):425-44. PubMed ID: 25117153
[TBL] [Abstract] [Full Text] [Related]
12. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
[TBL] [Abstract] [Full Text] [Related]
13. Afatinib for the treatment of advanced non-small-cell lung cancer.
Genova C; Rijavec E; Barletta G; Burrafato G; Biello F; Dal Bello MG; Coco S; Truini A; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Apr; 15(6):889-903. PubMed ID: 24646054
[TBL] [Abstract] [Full Text] [Related]
14. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
[TBL] [Abstract] [Full Text] [Related]
15. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract] [Full Text] [Related]
16. erbb4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract] [Full Text] [Related]
17. New developments in dermatological oncogenetics.
Kunz M
J Dtsch Dermatol Ges; 2013 Sep; 11(9):831-6. PubMed ID: 23957481
[TBL] [Abstract] [Full Text] [Related]
18. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.
Belleudi F; Marra E; Mazzetta F; Fattore L; Giovagnoli MR; Mancini R; Aurisicchio L; Torrisi MR; Ciliberto G
Cell Cycle; 2012 Apr; 11(7):1455-67. PubMed ID: 22421160
[TBL] [Abstract] [Full Text] [Related]
19. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Dutton-Regester K; Irwin D; Hunt P; Aoude LG; Tembe V; Pupo GM; Lanagan C; Carter CD; O'Connor L; O'Rourke M; Scolyer RA; Mann GJ; Schmidt CW; Herington A; Hayward NK
Mol Cancer Ther; 2012 Apr; 11(4):888-97. PubMed ID: 22383533
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear HER3 is associated with favorable overall survival in uveal melanoma.
Trocmé E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
Int J Cancer; 2012 Mar; 130(5):1120-7. PubMed ID: 21484789
[TBL] [Abstract] [Full Text] [Related]
[Next]